Discovery of a Novel CDK7 Inhibitor YPN-005 in Small Cell Lung Cancer

Investigators developed a potent inhibitor of cyclin-dependent kinase 7 (CDK7), designated YPN-005, and determined whether it showed any anticancer effects in small cell lung cancer (SCLC), cells, cisplatin or etoposide-resistant cells, or organoids derived from SCLC patients.